Intermittent complete heart block with ventricular standstill after Pfizer COVID‐19 booster vaccination: A case report by Ethan Kimball, Kyle Buchwalder, Cameron Upchurch, Bory Kea

“…Here, we report a novel case of intermittent complete heart block with ventricular standstill occurring within 24 hours of administration of a Pfizer‐BioNTech COVID‐19 booster vaccine. The patient presented to the emergency department (ED) via ambulance for evaluation of syncope. …”
Get full text

Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech by Lilia M. Sierra Galan, Raquel Cohen Shaooli

“…We present a 76-year-old male patient who developed delirium after receiving the second dose of the BNT162b2 mRNA vaccine from Pfizer Inc. and BioNTech®. We theorize about the potential pathophysiology mechanisms involved.…”
Get full text

Physiologic Response to the Pfizer-BioNTech COVID-19 Vaccine Measured Using Wearable Devices: Prospective Observational Study by Alexander G Hajduczok, Kara M DiJoseph, Brinnae Bent, Audrey K Thorp, Jon B Mullholand, Stuart A MacKay, Sabrina Barik, Jamie J Coleman, Catharine I Paules, Andrew Tinsley

“… BackgroundThe Pfizer-BioNTech COVID-19 vaccine uses a novel messenger RNA technology to elicit a protective immune response. …”
Get full text

Large Hemorrhagic Pericardial Effusion and Cardiac Tamponade Following BNT162b2 (BioNTech/Pfizer) Vaccine by Hien Nguyen, Michelle Nguyen, Angela Olenik

“…We report the first case of a hemorrhagic pericardial effusion with cardiac tamponade in a 52-year-old woman occurring one week following the second dose of the BNT162b2 (BioNTech/Pfizer) SARS-CoV-2 vaccination. The time sequence in this case report correlates with reports submitted to the Vaccine Adverse Event Reporting System (VAERS), which indicates that cases of pericarditis following mRNA vaccination most commonly occur within 1-2 weeks following the second dose of vaccination.…”
Get full text

Do Public Announcements of Drug Development Events Influence a Drug Company’s Market Value? A Study on Pfizer by Yu-Han Tsao, Chun-Chieh Wang

Subjects: Get full text

An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database) by Mitchell E. Geffner, Michael B. Ranke, Michael P. Wajnrajch, for the Pfizer International Growth Database Strategic Executive Committee, Strategic Advisory Board, and International Board

“…KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. …”
Get full text

Effectiveness and adverse effects of astrazeneca and pfizer COVID-19 vaccines among medical students in Oman: A comparative study by Mohan Bilikallahalli Sannathimmappa, Vinod Nambiar, Rajeev Aravindakshan, Muqeet Fauzan Baig, Ahmed Kifah Hassan, Maryam Saud Mohammed Al-Balushi

Subjects: Get full text

The Influence of Environmental Change on Pharmaceutical Companies -- Analysis of Opportunities for Pharmaceutical Companies, Take Roche Inc., Pfizer, and Merck. as an example by Lai Yingkuan

Get full text

Evaluating Pharmacists’ Pharmacological Knowledge and Views Regarding Pfizer-BioNTech COVID-19 Vaccine in Saudi Arabia by Alorfi N, Ashour A

Subjects: Get full text

Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine by Roberto Scendoni, Cristina Petrelli, Giorgia Scaloni, Francesco Ottavio Logullo

Subjects: “…pfizer-biontech covid-19 vaccine…”
Get full text

Development of Flat Warts on the Cheeks after BioNTech-Pfizer BNT162b2 Vaccine: Is There a Correlation? by Gerardo Cazzato, Paolo Romita, Caterina Foti, Debora Lobreglio, Irma Trilli, Anna Colagrande, Giuseppe Ingravallo, Leonardo Resta

“…We present a case of multiple flat warts onset over the cheeks in a patient after the second dose of mRNA BioNTech-Pfizer BNT162b2 vaccine, and we discuss the possible temporal association between the two events, also considering the patient’s antibody status.…”
Get full text

Humoral and Innate Immunological Profile of Paediatric Recipients of Pfizer-BioNTech BNT162b2 mRNA Vaccine by Sundararaj Stanleyraj Jeremiah, Priya Das, Manu Venkatesan, Reem Albinzayed, Aysha Ahmed, Nigel John Stevenson, Martin Corbally, Manaf Alqahtani, Fatima Al-Wedaie, Eman Farid, Suha Hejres

Subjects: “…Pfizer vaccine…”
Get full text

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination by Ariel Israel, Eugene Merzon, Yotam Shenhar, Ilan Green, Avivit Golan-Cohen, Alejandro A. Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen

Get full text

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis by Michael Jahn, Johannes Korth, Oliver Dorsch, Olympia Evdoxia Anastasiou, Burkhard Sorge-Hädicke, Bartosz Tyczynski, Anja Gäckler, Oliver Witzke, Ulf Dittmer, Sebastian Dolff, Benjamin Wilde, Andreas Kribben

“…We measured humoral immune responses in 72 HDP after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech). Antibody responses were evaluated with an anti-SARS-CoV-2 IgG ChemiLuminescent ImmunoAssay (CLIA) two weeks after the second dose. …”
Get full text

A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine by Immacolata Polvere, Serena Voccola, Alfredina Parrella, Gaetano Cardinale, Lucrezia Zerillo, Romualdo Varricchio, Jessica Raffaella Madera, Romania Stilo, Pasquale Vito, Tiziana Zotti

“…The coronavirus disease 2019 (COVID-19) mRNA vaccine developed by Pfizer/BioNTech has been shown to be capable of developing an excellent antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, with good production of neutralizing antibodies. …”
Get full text

Concurrent hypereosinophilic syndrome and deep vein thrombosis after Pfizer‐BioNTech COVID‐19 vaccination: A case report by Shungo Yano, Taiju Miyagami, Takayuki Furusaka, Nagamasa Kano, Toshio Naito

Get full text

Renal Biopsy Diagnosis of Acute Tubular Injury after Pfizer-BioNTech COVID-19 Vaccination: A Case Report by Yu Soma, Daiyu Kitaji, Kaoru Hoshino, Sumire Sunohara, Takehisa Iwano, Naomi Kawano

“…He was referred to our hospital 5 days after receiving the fourth Pfizer-BioNTech COVID-19 vaccine dose with stage 3 AKI. …”
Get full text

IgG Titer of Pfizer BNT62b2 COVID-19 Negatively Correlated with Soluble Inhibitory Immune Checkpoints by Selda Ezzaldeen, Haider Kadhim, Mohammed Tawfiq

“…Conclusion: This study showed a significant negative correlation between IgG titer of Pfizer BNT62b2 COVID-19 and soluble immune checkpoint markers and a moderate positive highly significant correlation among soluble inhibitory immune checkpoints. …”
Get full text

De novo Minimal Change Disease in an Adolescent after Pfizer-BioNTech COVID-19 Vaccination: A Case Report by Eva Pella, Pantelis A. Sarafidis, Maria-Eleni Alexandrou, Maria Stangou, Christina Nikolaidou, Dimitrios Kosmidis, Aikaterini Papagianni

“…This is the first report in an adolescent of minimal change disease (MCD) after the first injection of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech) with complete remission following steroid treatment. …”
Get full text

Cerebral Venous Thrombosis after SARS-CoV-2 Infection and Pfizer-BioNTech Vaccination against COVID-19 by Martina Nicolardi, Daniele Urso, Silvia Luceri, Giancarlo Logroscino, Roberto De Blasi

“…Here, we report a case of CVT diagnosed approximately 2 weeks after first dose of Pfizer-BioNTech vaccination, in a patient affected by COVID-19 few months earlier. …”
Get full text